A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
NCT06703021 on ClinicalTrials.gov · last registry update 2026-04-28
Finished 12 January 2026, after enrolling 85 people. Primary outcome, as filed: Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). aleniglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- COMPLETED
- Phase
- P2
- Drug
- aleniglipron
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Sponsor type
- Industry
- Enrollment
- 85
- Started
- 2024-12-20
- Primary completion
- 2026-01-12 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-21 | First seen in registry | Registered as COMPLETED, P2 |
Primary outcome
Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Conditions studied
Obesity · Overweight · Chronic Weight Management
Every field above is taken directly from the registry record. See all detected changes across the class, or the aleniglipron page for this molecule’s full trial and approval history.